Search Results 2221-2230 of 13400 for monoclonal antibody

  1. AB-2100, An Integrated Circuit T (ICT) Cell Therapy In Patients With Recurrent Clear-cell Renal Cell Carcinoma (CcRCC) - Mayo Clinic

    ... antibody-based agent). * Systemic anti-cancer therapy within 14 days of starting of conditioning chemotherapy (interval of 28 days will be required if the ...

  2. A Study To Evaluate Safety Of Long-term AL001 Dosing In FTD Patients - Mayo Clinic

    Participation eligibility · Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or ...

  3. Multi-center, Open-label, Single-ascending Dose Study Of Safety And Tolerability Of TN-201 In Adults With Symptomatic MYBPC3 Mutation-associated HCM - Mayo Clinic

    * High AAV9 neutralizing antibody titer. Note: Other protocol defined Inclusion/Exclusion Criteria may apply. Eligibility last updated 01/28/2026. Questions ...

  4. Amyotrophic Lateral Sclerosis (ALS) Clinical Trials - Mayo Clinic Research

    The purpose of this study is to determine the safety and efficacy of intrathecal treatment delivered to the cerebrospinal fluid (CSF) of mesenchymal stem cells ...

  5. (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis - Mayo Clinic

    ... antibody 6. History of clinically significant bleeding event within 30 days before the first dose of study drug or need for therapeutic anticoagulation on ...

  6. Exploring The Role Of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) In BAFFR-expressing B-cell Hematologic Malignancies And Autoimmune Rheumatologic Disorders - Mayo Clinic

    ... antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. Participation eligibility. Participant eligibility ...

  7. Meningococcal vaccine (intramuscular route) - Side effects & uses - Mayo Clinic

    The vaccine works by causing your body to produce its own protection (antibodies) against the disease. Meningococcal infection can cause life-threatening ...

  8. Study Of DISC-0974 (RALLY-MF) In Participants With Myelofibrosis Or Myelodysplastic Syndrome And Anemia - Mayo Clinic

    A history of antidrug antibody formation. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ...

  9. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can ...

  10. Medical Research & Education - Mayo Clinic News Network

    Convalescent plasma antibody levels and the risk of death from COVID-19 featured image · Diverse ways regenerative medicine is advancing health care featured ...